Erratum to: The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy

Gabriel Farante · Stefano Zurrída · Viviana Galimberti ·
Paolo Veronesi · Giuseppe Curigliano · Alberto Luini ·
Aron Goldhirsch · Umberto Veronesi

Published online: 21 September 2010
© Springer Science+Business Media, LLC. 2010

Erratum to: Breast Cancer Res Treat DOI 10.1007/s10549-010-1124-4

Under section “Guidelines for systemic treatment” it should read

(a) *ER-positive patients*: premenopausal and postmenopausal patients receive low-dose tamoxifen (20 mg/week) or participate in the IBIS-2 trial, which has two arms: after quadrantectomy, Tamoxifen (20 mg/day) versus Anastrozole (**1 mg/day**); after mastectomy, Anastrozole (**1 mg/day**) versus placebo.

Instead of

(a) *ER-positive patients*: premenopausal and postmenopausal patients receive low-dose tamoxifen (20 mg/week) or participate in the IBIS-2 trial, which has two arms: after quadrantectomy, Tamoxifen (20 mg/day) versus Anastrozole (**100 mg/day**); after mastectomy, Anastrozole (**100 mg/day**) versus placebo.

The online version of the original article can be found under doi:[10.1007/s10549-010-1124-4](https://doi.org/10.1007/s10549-010-1124-4).

G. Farante (✉) · S. Zurrída · V. Galimberti · P. Veronesi ·
A. Luini
Division of Senology, European Institute of Oncology,
IEO, Via Ripamonti 435, 20141 Milan, Italy
e-mail: gabriel.farante@ieo.it

S. Zurrída · P. Veronesi · G. Curigliano · A. Goldhirsch
Department of Medicine, European Institute of Oncology,
IEO, Milan, Italy

S. Zurrída · P. Veronesi · U. Veronesi
Scientific Directorate of the European Institute of Oncology,
IEO, Milan, Italy

S. Zurrída · P. Veronesi
School of Medicine, University of Milan, Milan, Italy